Anúncio
Anúncio

BRTX

BRTX logo

BioRestorative Therapies, Inc. Common Stock (NV)

1.21
USD
Patrocinado
+0.01
+0.42%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

1.21

0.00
0.00%

Relatórios de Lucros BRTX

Rácio de surpresa positiva

BRTX separação 12 de 15 últimas estimativas.

80%

Próximo Relatório

Data do Próximo Relatório
25 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$306.00K
/
-$0.38
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+2450.00%
/
+15.15%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+606.70%
/
+90.00%

BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue

On 12 de nov. de 2025, BRTX reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 10.13% surprise. Revenue reached 12.00 mil, compared to an expected 469.20 mil, with a -97.44% difference. The market reacted with a -9.42% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.38 USD, with revenue projected to reach 306.00 mil USD, implying an aumentar of 15.15% EPS, and aumentar of 2450.00% in Revenue from the last quarter.
FAQ
For Q3 2025, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of -$0.33, beating estimates by 10.13%, and revenue of $12.00K, -97.44% below expectations.
The stock price moved down -9.42%, changed from $1.38 before the earnings release to $1.25 the day after.
The next earning report is scheduled for 25 de mar. de 2026.
Based on 4 analistas, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.38 and revenue of $306.00K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio